Status:
COMPLETED
A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
To evaluate safety and immunogenicity of 2 different HIV-1 peptide candidate vaccines, the UBI HIV-1 MN PND peptide immunogen and the UBI microparticulate monovalent HIV-1 MN branched peptide when adm...
Detailed Description
After the prescreening, volunteers will be randomized into Group I or Group II. Each group will contain 16 volunteers. At least 5 volunteers in each group must be women. At month 0 all volunteers will...
Eligibility Criteria
Inclusion Criteria
Patients must have or be:
- Healthy.
- Negative ELISA for HIV.
- Negative for Hepatitis B surface antigen.
- Normal urine dipstick.
- Normal history and physical exam.
- Availability for follow-up for planned duration of the study (60 weeks).
Risk Behavior: Required:
- Lower or intermediate risk sexual behavior as defined by AVEG.
Exclusion Criteria
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
- Medical or psychiatric condition or occupational responsibilities which preclude subject compliance with the protocol.
- Active syphilis. NOTE: If the serology is documented to be a false positive or due to a remote (> 6 months) treated infection, the volunteer is eligible.
- Active tuberculosis. NOTE: Volunteers with a positive PPD and a normal chest X-ray showing no evidence of TB and not requiring INH therapy are eligible.
Patients with any of the following prior conditions are excluded:
- History of immunodeficiency, chronic illness, malignancy or autoimmune disease.
- History of anaphylaxis or other serious adverse reactions to vaccines.
- History of inflammatory gastrointestinal disease, celiac disease or intestinal malignancy.
- History of acute gastroenteritis within the past month or gastrointestinal surgery within the past 12 months.
Prior Medication:
Excluded:
- History of use of immunosuppressive medication.
- Live attenuated vaccines within 60 days of study. NOTE: Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) are not exclusionary but should be given at least 2 weeks away from HIV immunizations.
- Use of experimental agents within 30 days prior to study.
- Receipt of blood products or immunoglobulin in the past 6 months.
- Prior receipt of HIV vaccines or a placebo recipient in an HIV vaccine trial.
Risk Behavior:
Excluded:
- Subjects with identifiable higher risk behavior for HIV infection as determined by screening questionnaire designed to identify risk factors for HIV infection.
- History of injection drug use within the last 12 months to enrollment.
- Higher risk sexual behavior as defined by AVEG.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00000846
Last Update
June 24 2005
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Univ of Rochester Med Ctr
Rochester, New York, United States, 14642
3
Univ of Washington / Pacific Med Ctr
Seattle, Washington, United States, 98144